Key result
Titanium-nitride-oxide-coated stents cut 6-month major cardiovascular events by ~20 percentage points vs. stainless steel stents.
Why the study?
Stent coating with titanium-nitride-oxide reduces neointimal hyperplasia in a porcine restenosis model, prompting an investigation of the clinical safety and efficacy of titanium-nitride-oxide-coated stents compared with stainless steel stents.
Does a titanium-nitride-oxide-coated stent reduce restenosis and major adverse cardiac events compared with an identical stainless steel stent in patients with de novo coronary artery lesions?
RCT (n=92)
randomly assigned
Does a titanium-nitride-oxide-coated stent reduce restenosis and major adverse cardiac events compared with an identical stainless steel stent in patients with de novo coronary artery lesions?
In patients with de novo coronary lesions, titanium-nitride-oxide-coated stents significantly reduced neointimal hyperplasia, angiographic late loss, and 6-month major adverse cardiac events compared with bare stainless steel stents of identical design.
Answers are grounded in this paper and cite their sources.
TiNOX-coated stents reduce restenosis and MACE versus stainless steel; confirms preclinical benefits in the first human RCT.
BACKGROUND: Stent coating with titanium-nitride-oxide has been shown to reduce neointimal hyperplasia in the porcine restenosis model. We designed a prospective, randomized, clinical study to investigate the safety and efficacy of titanium-nitride-oxide-coated stents compared with stainless steel stents. METHODS AND RESULTS: Ninety-two patients with de novo lesions were randomly assigned to treatment with titanium-nitride-oxide-coated stents (n=45) or stainless steel stents of otherwise identical design (n=47; control). Baseline characteristics were similar in both groups. At 30 days, no stent thromboses or other adverse events had occurred in either group. Quantitative coronary angiography at 6 months revealed lower late loss (0.55+/-0.63 versus 0.90+/-0.76 mm, P=0.03) and percent diameter stenosis (26+/-17% versus 36+/-24%, P=0.04) in lesions treated with titanium-nitride oxide-coated than in control stents. Binary restenosis was reduced from 33% in the control group to 15% in the titanium-nitride oxide-coated stent group (P=0.07). Intravascular ultrasound studies at 6 months showed smaller neointimal volume in titanium-nitride-oxide-coated stents than in control stents (18+/-21 versus 48+/-28 mm3, P<0.0001). Major adverse cardiac events at 6 months were less frequent in titanium-nitride-oxide-coated stents than in control stent-treated patients (7% versus 27%, P=0.02), largely driven by a reduced need for target-lesion revascularization (7% versus 23%, P=0.07). CONCLUSIONS: Revascularization with titanium-nitride-oxide-coated stents is safe and effective in patients with de novo native coronary artery lesions. Titanium-nitride-oxide-coated stents reduce restenosis and major adverse cardiac events compared with stainless steel stents of otherwise identical design.
No takes yet. Share an insight, caveat, or question.
Windecker et al. (2005) conducted an RCT in De novo native coronary artery lesions (n=92). Titanium-nitride-oxide-coated stent vs. Stainless steel stent of otherwise identical design was evaluated on Major adverse cardiac events at 6 months (p=0.02). Titanium-nitride-oxide-coated stents reduced 6-month major adverse cardiac events and late lumen loss compared with stainless steel stents.
Synapse has enriched 10 related papers. Consider them for comparative context: